Navigation Links
TREVENTIS Corporation Founder Wins Prestigious Discovery Award

PHILADELPHIA and Nova Scotia, CANADA, Jan. 11, 2011 /PRNewswire/ -- TREVENTIS Corporation founder, Christopher Barden, Ph.D., was awarded "Emerging Professional Award" for his work in computer-aided drug design.  Dr. Barden received the Award at the 8th annual Discovery Awards dinner sponsored by Nova Scotia's Discovery Centre.  His work has provided TREVENTIS with a proprietary drug discovery system called the Common Conformational Motif (CCM).  

In addition, Company founder Sultan Darvesh, M.D., Ph.D., was one of only three finalists in the category of "Professional of Distinction" for his work and recognized expertise in the field of butyrylcholinesterase (BuChE) as a diagnostic and therapeutic target in diseases of the brain.  Dr. Darvesh heads the Company's efforts in developing a diagnostic test for Alzheimer's disease.  

Finalists and award winners are recognized by the Discovery Centre as the top science practitioners in Nova Scotia.  Three finalists are selected among all of Nova Scotia's scientific professionals in both the regular Professional and early-career Emerging categories.  The Discovery Awards "recognize the talented individuals...whose exemplary work in science and technology inspire us all," according to its web site (  Past recipients of the Discovery Award include TREVENTIS founder Donald Weaver, M.D., Ph.D., a neurologist and recognized expert in Alzheimer's disease.

"We are delighted to have the scientific foundation of the Company validated by this prestigious award," said Bill McIntosh, CEO of TREVENTIS Corporation.  "That they were nominated for these awards is clear recognition of the significant work they are doing for the Company and for science."

Dr. Barden is part of a team of TREVENTIS chemists and biologists who have discovered and synthesized multiple classes of therapeutic compounds that block the aggregation of misfolding proteins.  Misfolding proteins have been implicated in numerous CNS diseases including Parkinson's disease and Alzheimer's disease, the Company's current focus.  

About TREVENTIS Corporation

TREVENTIS Corporation, headquartered in Southeastern Pennsylvania, has research operations in Halifax, Nova Scotia, Canada.  The company is focused on the discovery and early stage development of disease-modifying, small molecule drugs for Alzheimer's and other protein misfolding diseases such as Parkinson's and Huntington's disease.  In addition to its therapeutics programs, TREVENTIS has a novel approach to the development of diagnostics for early diagnosis as well as monitoring treatment effects in Alzheimer's disease, MS and primary brain tumors.For more information contact:

L. William McIntosh, CEOTREVENTIS Corporationwww.TREVENTIS. and wmcintosh@treventis.com610-488-6081  

Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Saints Medical Center and ZOLL Medical Corporation Enter Collaborative Agreement
2. Luminex Corporation to Present at JP Morgan Healthcare Conference
3. SRI International Completes Integration of Sarnoff Corporation
4. Heska Corporation Announces Stockholder Approval of Reverse Split
5. Pfizer Animal Health to Acquire Synbiotics Corporation, Entering Diagnostics Sector
6. Webcast Alert: Heska Corporations Special Meeting of Stockholders Webcast
7. LodgeNet Healthcare, MDM Healthcare and Child Health Corporation of America Reach Agreement
8. VIDEO from Siemens Corporation Available on Amazing Medical Images: Diagnosing in the Digital Age
9. Heska Corporation Awards $25,000 Grand Prize to Pets Forever
10. Unilife Corporation Moves into New State-of-the-Art Manufacturing Facility and Global Headquarters
11. Oxford Finance Corporation Hires Debbie Baker to Support Life Science Business Development in Western North America
Post Your Comments:
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that it ... (procalcitonin) assay as a dedicated testing solution for people ... Roche is the first IVD company in the U.S ... assessment and management. PCT is a sepsis-specific ... blood can aid clinicians in assessing the risk of ...
(Date:6/23/2016)... , June 23, 2016 Bracket , ... launch its next generation clinical outcomes platform, Bracket eCOA (SM) ... held on June 26 – 30, 2016 in ... first electronic Clinical Outcome Assessment product of its kind to ... #715. Bracket eCOA 6.0 is a flexible platform ...
(Date:6/23/2016)... 23, 2016 Revolutionary technology includes ... Oticon , industry leaders in advanced audiology and hearing ... Oticon Opn ™, the world,s first internet connected hearing ... IoT devices.      (Photo: ... number of ,world firsts,: , TwinLink™ - ...
Breaking Medicine Technology:
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... ... cutting edge technology to revolutionize the emergency ambulance transport experience for the millions ... aware of how Uber has disrupted the taxi industry through the use of ...
(Date:6/26/2016)... ... , ... Pixel Film Studios Released ProSlice Levels, a Media Slicing Effect ... a whole new perspective by using the title layers in ProSlice Levels to ... ProSlice Levels contains over 30 Different presets to choose from. FCPX users ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the ... AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in ... topics including advance care planning, healthcare costs and patient and family engagement. , ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , ... Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. , ... our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, whether ... latter, setting the bar too high can result in disappointment, perhaps even self-loathing. However, ... their goal. , Research from reveals that behind the tendency ...
Breaking Medicine News(10 mins):